PT  - JOURNAL ARTICLE
AU  - Vinall, Phil
ED  - Terrault, Norah
TI  - Hepatitis C: The Impact of New and Future Therapeutics
DP  - 2012 Dec 01
TA  - MD Conference Express
PG  - 32--33
VI  - 12
IP  - 14
4099  - http://mdc.sagepub.com/content/12/14/32.short
4100  - http://mdc.sagepub.com/content/12/14/32.full
AB  - The burden of hepatitis C (HCV) in the United States now exceeds that of HIV and hepatitis B combined. It is estimated that from 2010 to 2019, 193,000 HCV-related deaths, direct medical care costs of $10.7 billion, and $75.3 billion in societal costs can be expected. HCV-associated liver related morbidity and mortality is an important component of this burden [Wong JB et al. Am J Public Health 2000]. This article discusses how antiviral therapy targeted to achieve viral eradication is the key strategy to stabilizing or reversing liver injury and fibrosis, and reducing the risk of liver-related complications, including cirrhosis and liver cancer, in patients with HCV.